Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor

Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor

Abstract Background 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT) was proposed as an imaging biomarker for the assessment of in vivo cellular proliferation with positron emission tomography (PET). The current study aimed to validate [18F]FLT as a perfusion-independent PET tracer, by gaining insight in...

Full description

Bibliographic Details
Main Authors: R. Iqbal, G. M. Kramer, V. Frings, E. F. Smit, O. S. Hoekstra, R. Boellaard, on behalf of the QuIC-ConCePT Consortium
Format: Article
Language:English
Published: SpringerOpen 2018-03-01
Series:EJNMMI Research
Subjects:
Positron emission tomography (PET)
Non-small cell lung cancer (NSCLC)
[18F]FLT
Perfusion
Tyrosine kinase inhibitors (TKIs)
Online Access:http://link.springer.com/article/10.1186/s13550-018-0376-6

Internet

http://link.springer.com/article/10.1186/s13550-018-0376-6

Similar Items